Feusisberg, Switzerland
Histide, founded in 2014 and headquartered in Switzerland, is at the forefront of innovative healthcare solutions with its proprietary Recoding Therapeutics. The company's pioneering technology leverages non-mutagenic extracellular technologies to influence cell fate, an approach that is fundamentally safer and more effective than traditional gene and RNA therapies, as it avoids introducing foreign molecules into cells.
Histide's platform, based on a deep understanding of mammalian cell behavior, creates microenvironments that allow for precise control over cell biology, facilitating the regeneration of human tissues. This breakthrough has potential applications across various sectors including pharmaceuticals, medical devices, and medical cosmetics. Histide's robust intellectual property portfolio and its international collaborations with leading research institutions underscore its innovative edge.
In its early phase, Histide secured a Fr.4.50M Series A investment from Partner Capital and Open Field Capital on 10 November 2014, revealing strong investor confidence and setting the stage for future growth in the Biotechnology and Health Care sectors.
